UBS upgraded Roche (RHHBY) to Buy from Neutral with a price target of CHF 338, up from CHF 300. The company offers sustainable growth with margin leverage, the analyst tells investors in a ...

Morgan Stanley initiated coverage of Roche (RHHBY) with an Equal Weight rating and CHF 305 price target The firm sees the end of Roche’s earnings downgrade cycle, with a pick up in “high risk ...

To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, ...

Roche has obtained U.S. government green lights allowing its point-of-care testing system to be used to screen for multiple sexually transmitted infections from a single sample. The company’s ...

Basel, 04 February 2025 - Roche (SIX: RO, ROG ... macular edema (DME), a leading cause of vision loss in adults with diabetes, affecting more than 29 million adults worldwide.

Basel, 04 February 2025 - Roche ... with diabetes, affecting more than 29 million adults worldwide. 1-3 Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

"People with Type 1 diabetes now live normal lifespans, and it is crucial to study this population to ensure they receive the best possible care." This research marks the first time the Doctors ...

What does this mean for diabetes care and prevention? Study: Burden of micronutrient deficiency among patients with type 2 diabetes: systematic review and meta-analysis. Image Credit: Halfpoint ...

The Canadian Generic Pharmaceutical Association (CGPA) is pleased to announce the unanimous election of Michel Robidoux, ...